Association Between Copy-number Alteration of +20q, -14q and -18p and Cross-sensitivity to Tyrosine Kinase Inhibitors in Clear-cell Renal Cell Carcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2020 Oct 12

PMID 33041663

Citations 3

Authors

Liang Wang

Yuqing Li

Yinfeng Lyu

Hui Wen

Chenchen Feng

Affiliations

Soon will be listed here.

Abstract

Background: We aim to explore association between copy number alteration (CNA) and sensitivity to common tyrosine kinase inhibitors (TKIs) used in clear-cell renal cell carcinoma (ccRCC) treatment.

Methods: CNA with related sensitivity profiles were extracted from the Genomics of Drug Sensitivity in Cancer (GDSC) dataset and was cross-referenced with common CNA in ccRCC in the Cancer Genome Atlas (TCGA) dataset. Functional annotation was profiled using GSEA and NET-GE. Target genes within cytobands of interest were screened in silico and validated in vitro using proliferation assays in A498 and 786-O ccRCC cells.

Results: Four TKIs (Sunitinib, Cabozantinib, Axitinib and Sorafenib) that were clinically used in ccRCC were selected. In silico analysis showed gain of 20q (+20q) occurred in ~ 23% of cases and was associated with resistance to all four TKIs; loss of 14q (-14q) occurred in ~ 39% of cases and was associated with resistance to Sunitinib and Sorafenib; loss of 18p (-18p) occurred in ~ 39% of cases and was associated with sensitivity to Sunitinib and Sorafenib. All 3 CNAs were associated with worsened prognosis, respectively. Candidate target genes included of RBL1 on 20q, KLHL33 on 14q and ARHGAP28 on18q. In vitro validation showed RBL1 overexpression induced resistance to Sunitinib and Cabozantinib; KLHL33 silencing induced resistance to Sunitinib; ARHGAP28 silencing induced sensitivity to Cabozantinib. Functional annotation indicated FoxO signaling, hypoxic response and Wnt pathway, and Rho-related cellular adhesion were mechanistically associated with +20q, -14q and -18p, respectively.

Conclusion: Common CNAs in ccRCC are associated with cancer-intrinsic cross-sensitivity to common TKIs. Further validation and functional analyses are therefore needed.

Citing Articles

Pan-cancer analysis of kinesin family members with potential implications in prognosis and immunological role in human cancer.

Zhong M, Gong L, Li N, Guan H, Gong K, Zhong Y Front Oncol. 2023; 13:1179897.

PMID: 37711200 PMC: 10498125. DOI: 10.3389/fonc.2023.1179897.

Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.

Yoshikawa Y, Yamada Y, Emi M, Atanesyan L, Smout J, de Groot K Cancer Sci. 2021; 113(1):297-307.

PMID: 34687579 PMC: 8748218. DOI: 10.1111/cas.15170.

BCL2L2 loss renders -14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors.

Lyu Y, Li K, Li Y, Wen H, Feng C Clin Transl Med. 2021; 11(3):e348.

PMID: 33784008 PMC: 7933017. DOI: 10.1002/ctm2.348.

References

Moore L, Jaeger E, Nickerson M, Brennan P, de Vries S, Roy R . Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis. 2013; 1:e14. PMC: 3412648. DOI: 10.1038/oncsis.2012.14. View

Hirata H, Matsuyama H, Matsumoto H, Korenaga Y, Ohmi C, Sakano S . Deletion mapping of 18q in conventional renal cell carcinoma. Cancer Genet Cytogenet. 2005; 163(2):101-5. DOI: 10.1016/j.cancergencyto.2005.03.010. View

Rini B, Powles T, Atkins M, Escudier B, Mcdermott D, Suarez C . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019; 393(10189):2404-2415. DOI: 10.1016/S0140-6736(19)30723-8. View

Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View

Motzer R, Haas N, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E . Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017; 35(35):3916-3923. PMC: 6018511. DOI: 10.1200/JCO.2017.73.5324. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez J . Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. 2018; 173(3):581-594.e12. PMC: 5938365. DOI: 10.1016/j.cell.2018.03.057. View

Motzer R, Penkov K, Haanen J, Rini B, Albiges L, Campbell M . Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1103-1115. PMC: 6716603. DOI: 10.1056/NEJMoa1816047. View

Korashy H, Maayah Z, Al Anazi F, Alsaad A, Alanazi I, Belali O . Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways. Anticancer Res. 2017; 37(9):4899-4909. DOI: 10.21873/anticanres.11899. View

10.

Beroukhim R, Brunet J, Di Napoli A, Mertz K, Seeley A, Pires M . Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69(11):4674-81. PMC: 2745239. DOI: 10.1158/0008-5472.CAN-09-0146. View

11.

Junker K, Weirich G, Amin M, Moravek P, Hindermann W, Schubert J . Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res. 2003; 162:169-75. DOI: 10.1007/978-3-642-59349-9_15. View

12.

Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir N . Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009; 125(10):2342-8. PMC: 2768265. DOI: 10.1002/ijc.24642. View

13.

Kim S, Park M, Yee S, Ji K, Lee E, Nguyen T . Axl is a key regulator of intestinal γδ T-cell homeostasis. FASEB J. 2019; 33(12):13386-13397. DOI: 10.1096/fj.201901356R. View

14.

Ravaud A, Motzer R, Pandha H, George D, Pantuck A, Patel A . Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016; 375(23):2246-2254. DOI: 10.1056/NEJMoa1611406. View

15.

El-Mokadem I, Fitzpatrick J, Bondad J, Rauchhaus P, Cunningham J, Pratt N . Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery. Br J Cancer. 2014; 111(7):1381-90. PMC: 4183850. DOI: 10.1038/bjc.2014.420. View

16.

Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S . Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Appl Immunohistochem Mol Morphol. 2015; 25(1):39-43. DOI: 10.1097/PAI.0000000000000257. View

17.

Parr C, Ali A . Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling. J Transl Med. 2018; 16(1):281. PMC: 6186110. DOI: 10.1186/s12967-018-1660-y. View

18.

Peng Q, Wang L, Zhao D, Lv Y, Wang H, Chen G . Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma. J Cancer. 2019; 10(5):1237-1251. PMC: 6400675. DOI: 10.7150/jca.28662. View

19.

Gong L, Shi J, Shang J, Hao J, Du X . Effect of miR-34a on resistance to sunitinib in breast cancer by regulating the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(3):1151-1157. DOI: 10.26355/eurrev_201902_17006. View

20.

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo R, Kolenko V . Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther. 2018; 17(7):1355-1364. PMC: 6034114. DOI: 10.1158/1535-7163.MCT-17-1299. View